Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | AK104 |
Trade Name | |
Synonyms | AK-104|AK 104 |
Drug Descriptions |
AK104 is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513). |
DrugClasses | Immune Checkpoint Inhibitor 153 PD-L1/PD-1 antibody 100 |
CAS Registry Number | 2233593-44-5 |
NCIT ID | C153379 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AK104 | AK104 | 0 | 2 |
AK104 + AK119 | AK104 AK119 | 0 | 1 |
AK104 + AK127 | AK104 AK127 | 0 | 1 |
AK104 + Anlotinib | AK104 Anlotinib | 1 | 0 |
AK104 + Capecitabine + Oxaliplatin | AK104 Capecitabine Oxaliplatin | 0 | 0 |
AK104 + Lenvatinib | AK104 Lenvatinib | 0 | 0 |